Dinutuximab beta

Unituxin

3.5 MG / ML SolutionCanadaMarketedAuthorised 1 May 2019

In other countries

The same active substances on other registers, the same brand first.

UnituxinEuropean Union · United Therapeutics Europe LtdSame brand
UnituxinUnited States · 17.5MG/5ML · injectable · United TherapSame brand
Qarziba 4,5 MG/ML Concentrado Para Solucion Para PerfusionSpain · 4,5 mg · concentrado para solución para perfusión · Recordati Netherlands B.V.Same substance
Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)European Union · Recordati Netherlands B.V.Same substance
Oportuzumab monatox DLRC Pharma ServicesEuropean Union · DLRC Pharma Services LtdSame substance
QarzibaCroatiaSame substance
Qarziba

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Dinutuximab beta

Unituxin

3.5 MG / ML SolutionCanadaMarketedAuthorised 1 May 2019

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Italy · Concentrato per soluzione per infusione · Recordati Netherlands B.V.

Qarziba 4.5 mg/ml, concentraat voor oplossing voor infusieNetherlands · Concentraat voor oplossing voor infusie · EUSA Pharma (Netherlands) B.V.

QARZIBA 4,5 mg/mlRomania · 4,5 mg/ml · conc. pt. sol. perf. · Eusa Pharma (Netherlands)B.V.

Documents

The official texts, at the regulator.

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Dinutuximab beta
Strength: 3.5 MG / ML
Dosage form: Solution
Route: Intravenous
Register: Canada (Health Canada)
Status: Marketed
Authorised: 1 May 2019
Registration: DIN 02483076
Marketing authorisation holder: United Therapeutics Corporation
ATC code: L01FX06
Group: Antineoplastic and immunomodulating agents
Supply: PRESCRIPTION